These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 2433373

  • 1. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP.
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [Abstract] [Full Text] [Related]

  • 2. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA, Lawrence RA, Jones RL, Wilson NH, Collier A.
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1.
    Oyekan AO, Botting JH.
    Prostaglandins; 1987 Sep; 34(3):359-66. PubMed ID: 3324168
    [Abstract] [Full Text] [Related]

  • 4. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition.
    Siess W, Lapetina EG.
    Biochem J; 1990 Nov 01; 271(3):815-9. PubMed ID: 1700902
    [Abstract] [Full Text] [Related]

  • 5. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR, Belch JJ, Lowe GD, Barbenel JC, Forbes CD.
    Haemostasis; 1987 Nov 01; 17(3):147-53. PubMed ID: 2440771
    [Abstract] [Full Text] [Related]

  • 6. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V, Stemerman M, Schafer A, Adelman B, Smith M, Fuhro R, Salzman E.
    J Lab Clin Med; 1985 Nov 01; 106(5):551-61. PubMed ID: 2997353
    [Abstract] [Full Text] [Related]

  • 7. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV, Aiken JW, Shebuski RJ, Gorman RR.
    Prostaglandins; 1980 Aug 01; 20(2):391-400. PubMed ID: 6251513
    [Abstract] [Full Text] [Related]

  • 8. Developmental Differences in Platelet Inhibition Response to Prostaglandin E1.
    Palma-Barqueros V, Torregrosa JM, Caparrós-Pérez E, Mota-Pérez N, Bohdan N, Llanos MDC, Begonja AJ, Sola-Visner M, Vicente V, Teruel-Montoya R, Rivera J, Ferrer-Marín F.
    Neonatology; 2020 Aug 01; 117(1):15-23. PubMed ID: 31786577
    [Abstract] [Full Text] [Related]

  • 9. Control of human and animal platelet aggregation by a new prostacyclin analog.
    Maderna P, Colli S, Sirtori C, Tremoli E, Paoletti R.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Aug 01; 13():363-9. PubMed ID: 2408447
    [Abstract] [Full Text] [Related]

  • 10. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE, Hallam TJ, Brown AM, Boyfield I, Cooper DG, Hickey DM, Jaxa-Chamiec AA, Kaumann AJ, Keen M, Kelly E.
    Br J Pharmacol; 1991 Jan 01; 102(1):251-9. PubMed ID: 1710526
    [Abstract] [Full Text] [Related]

  • 11. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A, Michael-Hepp J, Meyer J, Darius H.
    Eur J Pharmacol; 1995 May 26; 289(3):455-61. PubMed ID: 7556414
    [Abstract] [Full Text] [Related]

  • 12. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
    Armstrong RA, Jones RL, MacDermot J, Wilson NH.
    Br J Pharmacol; 1986 Mar 26; 87(3):543-51. PubMed ID: 3026540
    [Abstract] [Full Text] [Related]

  • 13. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
    Anfossi G, Massucco P, Mularoni E, Cavalot F, Mattiello L, Trovati M.
    Prostaglandins Leukot Essent Fatty Acids; 1993 Nov 26; 49(5):839-45. PubMed ID: 7508131
    [Abstract] [Full Text] [Related]

  • 14. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01s.
    Watanabe T, Yatomi Y, Sunaga S, Miki I, Ishii A, Nakao A, Higashihara M, Seyama Y, Ogura M, Saito H.
    Blood; 1991 Nov 01; 78(9):2328-36. PubMed ID: 1718495
    [Abstract] [Full Text] [Related]

  • 15. Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.
    Mardla V, Kobzar G, Samel N.
    Platelets; 2004 Aug 01; 15(5):319-24. PubMed ID: 15370103
    [Abstract] [Full Text] [Related]

  • 16. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
    Jaschonek K, Faul C, Daiss W, Weisenberger H.
    Prostaglandins Leukot Med; 1986 Oct 01; 24(2-3):199-206. PubMed ID: 2432618
    [Abstract] [Full Text] [Related]

  • 17. Platelet-stimulated thrombin and PDGF are normalized by insulin and Ca2+ channel blockers.
    Kahn NN.
    Am J Physiol; 1999 May 01; 276(5):E856-62. PubMed ID: 10329979
    [Abstract] [Full Text] [Related]

  • 18. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets.
    Ashby B.
    Mol Pharmacol; 1990 Jul 01; 38(1):46-53. PubMed ID: 1695318
    [Abstract] [Full Text] [Related]

  • 19. Sub-aggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation.
    Buttrick PM, Forscher CA, Sussman II, Mueller HS.
    Am Heart J; 1985 Jun 01; 109(6):1258-63. PubMed ID: 2988323
    [Abstract] [Full Text] [Related]

  • 20. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY, McGiff JC, Sun FF, Lee WH.
    Eur J Pharmacol; 1979 Dec 07; 60(2-3):245-8. PubMed ID: 393526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.